Management of Thrombocytopenia in CML Patients on TKI Therapy

Understanding TKI-Induced Thrombocytopenia

Myelosuppression, including thrombocytopenia, is very common during TKI treatment of CML and is due to the combined effect of suppressing the leukemic clone while also inhibiting normal hematopoiesis 1
Thrombocytopenia is often limited to the first weeks or months of treatment, with the incidence of grade 3-4 myelosuppression highest at treatment initiation 2
Hematological side effects of TKIs are generally dose-dependent and reversible upon treatment cessation or dose reduction 2
Thrombocytopenia represents a significant concern as it's a major cause of treatment discontinuation/interruption and dose reduction 2

For persistent thrombocytopenia, consider bone marrow examination to differentiate between persistence of leukemia and hypocellularity, consider growth factors to facilitate platelet recovery, and consider switching to a different TKI if thrombocytopenia persists 3

Consider G-CSF and erythropoietic agents transiently to facilitate hematologic recovery, as the concomitant use of growth factors with TKIs is effective and doesn't appear to be associated with lower response or TKI failure 4
For patients with platelet counts ≤10 × 10^9/L or between 10-20 × 10^9/L with fever/infection, platelet transfusions may be necessary 5

Monitor blood counts weekly for the first 4-6 weeks of treatment, then every 2 weeks or monthly until month 3, and subsequently every 3 months in chronic phase CML, with more frequent monitoring for patients with advanced disease 5

Myelosuppression is often an expression of TKI efficacy rather than true toxicity, and typically becomes rare once remission is achieved 2
Cross-intolerance can occur when switching TKIs, with recurring grade 3-4 cytopenias after switching appearing more common with dasatinib (86%) than with nilotinib (55%) 6
Avoid unnecessary antimicrobial prophylaxis in mild cases of leukopenia/thrombocytopenia to prevent antibiotic resistance 7
Be aware that TKIs, especially dasatinib, can induce platelet dysfunction, so antiplatelet therapy must be used carefully 4